Allium Medical wins Chinese marketing urological stent nod

Stent Photo: Shutterstock
Stent Photo: Shutterstock

The approval means that the company's agreement with a Chinese distributor will go into effect.

The share price of Allium Medical Ltd. (TASE: ALMD) rose 12.5% earlier this week following an announcement that the company had obtained marketing approval for its urological stent in China. Under the terms of a previously signed distribution agreement, a Chinese company will now order NIS 88 million worth of products from Allium Medical over eight years (NIS 11 million a year). Allium Medical believes that sales will begin this year. The surge in the company's share price boosted its market cap to NIS 88 million.

Allium Medical also announced that it had obtained marketing approval in Russia for its gynecological product for treatment of pelvic floor prolapse.

Allium Medical is a multidisciplinary medical devices company that develops urological stents and gynecological surgical solutions and sells them worldwide, while also developing complex implants that have not yet reached the sales stage.

Allium Medical's revenue from its urological and gynecological products has been growing slowly but steadily in recent years. The company posted NIS 7.7 million in revenue in 2017, 8% more than in 2016. If the Chinese distributor does make the expected orders, it is likely to have a substantial effect on the company.

Allium Medical has consistently lost money as a result of its investments in its more complex products, including NIS 22 million in 2017, most of it in operating loss. While the products being sold give the company's its stability, most of its current value comes from the potential of its "dream products." The leading such product as of now is a device for preventing embolisms in surgery. This product has already received marketing approval, and the company is looking for a strategic partner or buyer for it. The product has had approval for prevention of embolisms in the common carotid artery for a few months, and approval was also obtained two months ago for the same product for prevention of embolisms in the peripheral artery. The company said on that occasion that this approval was likely to lead to a deal, but no advanced negotiations for a deal have been announced so far, and obviously no such deal has been signed.

Allium Medical has added two more products to its portfolio in recent years: a sleeve surgery product for treatment of diabetes and obesity and a product for replacement of the mitral valve - one of the most attractive medical devices markets. These two products are in animal trials, while the product for diabetes and obesity is scheduled to enter human trials this year.

As of the end of 2017, Allium Medical had NIS 22 million in cash, after spending NIS 18.4 million on current activity during the year.

Allium Medical CEO Asaf Alperovitz said, "The Chinese market represents a huge opportunity for us, both because of its size and the trends in it and because of cooperation and the distribution agreement with our distributor in China, which has decades of experience and specialization in the urological market in China, plus broad geographic deployment there, both direct and through a sub-distributor. This distributor also has a widespread network of connections with leading urologists in China, some of whom participated in the company's clinical workshops in Germany and Italy. These urologists have expressed great enthusiasm about the company's products, which constitute a safe and effective alternative to surgical procedures and short-term solutions. In accordance with Chinese culture and medicine, doctors and patients in China strongly prefer minimally invasive solutions in the long term to surgical procedures, and some of the company's stent systems can be implanted in a clinic outside hospitals. The doctors believe that this will make the products accessible to additional territories and market segments beyond the main cities. Due to the combination of these factors, we believe that our stent systems have very significant clinical and commercial potential in this market."

Published by Globes [online], Israel business news - www.globes-online.com - on May 11, 2018

© Copyright of Globes Publisher Itonut (1983) Ltd. 2018

Stent Photo: Shutterstock
Stent Photo: Shutterstock
Unframe founders credit: Yossi Yarom Israeli AI enterprise platform co Unframe raises $50m

Unframe’s turnkey AI solutions enable companies to solve any enterprise AI use case at scale with fully functional, customized AI solutions for businesses in a matter of hours, rather than months.

Combatica credit: Combatica Combatica launches next-gen VR AI training platform

The Israeli company's virtual reality platform includes 50 AI generated scenarios, seven maps and even situations for operating night vision.

Shekel credit: Shutterstock Vladirina 32 Shekel volatility after US tariffs announcement

The shekel is weakening sharply against the euro, which is gaining following the unveiling of Donald Trump's tariffs plan.

Minister of Finance Bezalel Smotrich credit: Noam Moskovitz Knesset Spokesperson Treasury assesses potential damage to Israel's US exports

Israel will be charged a higher tariff on its exports to the US - its biggest export customer - than Turkey and the UAE.

Iranian flag credit: Shutterstock Why inflation haunts Iran

With a month-on-month increase of 3.3% and an annual rate of 37.1%, inflation reflects the struggles of millions of Iranians.

APM merges with lawyers from Doron, Tikotzky Kantor, Gutman credit: Eyal Merilos APM merges with 12 lawyers from Doron, Tikotzky Kantor, Gutman

With the addition of these 12 lawyers, Amit Pollak Matalon & Co. will now have 135 lawyers.

US President Donald Trump credit: Reuters Sipa USA Israel on list as Trump unveils tariffs

Relatively low reciprocal tariffs will be imposed on Israeli goods sold in the US.

Deflated unicorn credit: Shutterstock Big Tech 50 reports more huge falls in startup valuations

Israeli R&D partnership Big Tech 50 reports that an investment of $2 million in Orcam made in 2021, shrank to just $31,000 at the end of 2024.

NextFerm technologies based on yeast credit: NextFerm Food-tech co NextFerm suspends operations

The company, which produces food ingredients in yeast without genetic engineering, cannot pay its debts and is seeking a buyer.

Minister of Finance Bezalel Smotrich credit: Shlomi Yosef OECD sees recovery in growth but high inflation

The OECD Israel Economic Survey 2025 recommends that the Israeli government take several restraining measures, in order to exit the economic storm created by the war.

Dano Ben-Hur credit: Dror Sithakol Statisticians contradict BoI on impact of housing finance deals

The Central Bureau of Statistics insists the impact of 20/80 buy now pay later financing deals on the real estate market and housing prices is minimal.

Governor of the Bank of Israel Amir Yaron  credit: Government Press Office Debt fears top Bank of Israel's concerns

Most unusually, Governor of the Bank of Israel Amir Yaron's press conference last week did not focus on inflation and the impending interest rate decision.

US President Donald Trump  credit: Reuters/Leah Millis Israel moves to avoid Trump's tariffs axe

Minister of Finance Bezalel Smotrich has signed an order canceling all tariffs on imports from the US. The impact will mostly be on agricultural produce.

Forbes Rich List credit: Shutterstock Maslowski Marcin Wiz founders ranked in Forbes 2025 Rich List

There are a few dozen Israelis listed in the 2025 Forbes Real-Time Billionaires List including Wiz founders Assaf Rappaport, Yinon Costica, Roy Reznik and Ami Luttwak.

SatixFy CEO Nir Barkan credit: Ariel Barkan Canada's MDA Space to buy Israeli satcom co SatixFy

MDA Space will pay $269 million for the Israeli company, including taking on a $76 million debt and a 75% premium on SatixFy's closing price on Nasdaq yesterday.

Raising dollars credit: Shutterstock Israeli startups raised over $1b in March

Israeli privately-held tech companies have raised $2.1 billion in the first three months of 2025, according to IVC-LeumiTech, up 24% from the corresponding quarter of 2024.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018